Successful Noninvasive Ventilation and Enzyme Replacement Therapy in an Adult Patient with Morbus Hunter

  • M. WesthoffEmail author
  • P. Litterst
Research Report
Part of the JIMD Reports book series (JIMD, volume 5)


M. Hunter is characterized by an accumulation of mucopolysaccharides in cells, blood, and connective tissue as a consequence of a deficiency of the enzyme iduronate-2-sulfatase. Unlike enzyme replacement therapy with idursulfase in children, there is limited long-term experience in adult patients with Morbus Hunter.

The case presented here describes the development of a man born in 1971 who was admitted to Hemer Lung Clinic in 2005 with severe obstructive sleep apnea, pulmonary functional impairment, and ventilatory failure (FEV 1: 0.8 L, VC: 1.0 L; pO2: 52 mmHg; pCO2: 81 mmHg, 6 MWT: 100 m). Initially, the patient received symptomatic treatment with noninvasive ventilation, which achieved a considerable improvement in pulmonary function and a normalization of blood gasses. Since February 2008, the patient received additional enzyme replacement therapy with idursulfase, which resulted in a further significant functional improvement (FEV1: 1.6; VC: 2.3 L; VO2max: 1,350 mL or 28.1 mL/kg body weight), in a normalization of prior elevated pulmonary artery pressures and also in impressive changes in the physiognomy and joint mobility. In November 2010, the polysomnography and nocturnal blood gas analysis without NIV showed only a mild obstructive sleep-related breathing disorder with no sign of hypoventilation. Therapy was changed to nocturnal CPAP therapy with a constant pressure of 6 cm H2O. Additional administration of oxygen was not required. With this therapy, the patient has been asymptomatic up to September 2011.

Adult Hunter patients also benefit from enzyme replacement therapy and, in restrictive ventilatory defects with hypoventilation, from symptomatic therapy with noninvasive ventilation.


Continuous Positive Airway Pressure Enzyme Replacement Therapy Total Lung Capacity Continuous Positive Airway Pressure Therapy Tracheal Stenosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Six-minute walk test


Apnea/hypopnea index


Blood gas analysis


Continuous positive airway pressure


Diffusing capacity of the lung for carbon monoxide


Forced expiratory volume in 1 s


Forced vital capacity




Inter ventricular septum




Noninvasive ventilation


Negative airway pressure

PA syst.

Pulmonary artery systolic pressure


Partial pressure of carbon dioxide


Maximal inspiration pressure


Partial pressure of oxygen


Total lung capacity


Vital capacity


Maximum oxygen uptake


  1. Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017PubMedCrossRefGoogle Scholar
  2. Beck M (2011) Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment. Curr Pharm Biotechnol 12:861–866PubMedCrossRefGoogle Scholar
  3. Burrow TA, Leslie ND (2008) Review of the use of idursulfase in the treatment of mucopolysaccharidosis II. Biologics 2:311–320PubMedGoogle Scholar
  4. Davitt SM, Hatrick A, Sabharwal T, Pearce A, Gleeson M, Adam A (2002) Tracheobronchial stent insertions in the management of major airway obstruction in a patient with Hunter syndrome (type II mucopolysaccharidosis). Eur Radiol 12:458–462PubMedCrossRefGoogle Scholar
  5. Ginzburg AS, Onal E, Aronson RM, Schild JA, Mafee MF, Lopata M (1990) Successful use of nasal-CPAP for obstructive sleep apnea in Hunter syndrome with diffuse airway involvement. Chest 97:1496–1498PubMedCrossRefGoogle Scholar
  6. Gross ER, Lemmens HJ (2010) Hunter syndrome in an adult: beware of tracheal stenosis. Anesth Analg 110:642–643PubMedCrossRefGoogle Scholar
  7. Jones SA, Almássy Z, Beck M et al (2009) Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 32:534–543PubMedCrossRefGoogle Scholar
  8. Kamin W (2008) Diagnosis and management of respiratory involvement in Hunter syndrome. Acta Paediatr 97:57–60CrossRefGoogle Scholar
  9. Kurihara M, Kumagai K, Goto K, Imai M, Yagishita S (1992) Severe type Hunter´s syndrome. Polysomnographic and neuropathological study. Neuropediatrics 23:248–256PubMedCrossRefGoogle Scholar
  10. Le Guern E, Couillin P, Oberlé I, Ravise N, Boue J (1990) More precise localization of the gene for Hunter syndrome. Genomics 7:358–362PubMedCrossRefGoogle Scholar
  11. Leighton SE, Papsin B, Vellodi A, Dinwiddie R, Lane R (2001) Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 58:127–138PubMedCrossRefGoogle Scholar
  12. Martin R, Beck M, Eng C et al (2008) Recognition and diagnosis of mucopolysaccaridosis II (Hunter syndrome). Pediatrics 121:e377–e386PubMedCrossRefGoogle Scholar
  13. Morehead JM, Parsons DS (1993) Tracheobronchomalacia in Hunter´s syndrome. Int J Pediatr Otorhinolaryngol 26:255–261PubMedCrossRefGoogle Scholar
  14. Muenzer J, Wraith JE, Beck M et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465–473PubMedCrossRefGoogle Scholar
  15. Muenzer J, Beck M, Eng CM et al (2009) Multidisciplinary management of Hunter syndrome. Pediatrics 124:e1228–e1239PubMedCrossRefGoogle Scholar
  16. Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS et al (eds) The metabolic and molecular bases of inherited disease, 8th edn. Mc Graw-Hill, New York, pp 3421–3452Google Scholar
  17. Okuyama T, Tanaka A, Suzuki Y et al (2010) Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab 99:18–25PubMedCrossRefGoogle Scholar
  18. Orliaguet O, Pépin JL, Veale D, Kelkel E, Pinel N, Lévy P (1999) Hunter´s syndrome and associated sleep apnoea cured by CPAP and surgery. Eur Respir J 13:1195–1197PubMedCrossRefGoogle Scholar
  19. Pérez-Calvo J, Bergua Sanclemente I, López Moreno MJ et al (2011) Early response to idursulfase in a 31-year old male patient with Hunter syndrome. Rev Clin Esp 211:e42–e45PubMedCrossRefGoogle Scholar
  20. Sasaki CT, Ruiz R, Gaito R Jr, Kirchner JA, Seshi B (1987) Hunter’s syndrome: a study in airway obstruction. Laryngoscope 97:280–285PubMedCrossRefGoogle Scholar
  21. Shapiro J, Strome M, Crocker AC (1985) Airway obstruction and sleep apnea in Hurler and Hunter syndromes. Ann Otol Rhinol Laryngol 94:458–461PubMedGoogle Scholar
  22. Wraith JE, Scarpa M, Beck M et al (2008) Mucopolysaccaridosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267–277PubMedCrossRefGoogle Scholar
  23. Yoskovith A, Tewfik TL, Brouillette RT, Schloss MD, Der Kaloustian VM (1998) Acute airway obstruction in Hunter syndrome. Int J Pediatr Otorhinolaryngol 44:273–278CrossRefGoogle Scholar
  24. Young ID, Harper PS (1979) Long-term complications in Hunter´s syndrome. Clin Genet 16:125–132PubMedCrossRefGoogle Scholar
  25. Young ID, Harper PS (1982) Mild form of Hunter´s syndrome: clinical delineation based on 31 cases. Arch Dis Child 57:828–836PubMedCrossRefGoogle Scholar
  26. Young ID, Harper PS (1983) The natural history of the severe form of Hunter´s syndrome: a study based on 52 cases. Dev Med Child Neurol 25:481–489PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Department of PneumologyHemer Lung ClinicHemerGermany

Personalised recommendations